Wandercraft is a Paris-based medical robotics company that has developed the Atalante exoskeleton — a self-balancing, CE-marked robotic exoskeleton for rehabilitation of patients with lower limb paralysis due to stroke, spinal cord injury, or multiple sclerosis. With more than €50 million raised, the Atalante deployed in more than 30 rehabilitation hospitals across Europe, and France 2030 medical robotics funding supporting continued development, Wandercraft represents French engineering excellence in a medical technology field with immense social and commercial importance. The company has achieved what most exoskeleton startups have not: regulatory clearance, clinical deployment at scale, and a credible business model — making it Europe’s leading rehabilitation exoskeleton company and a benchmark for France 2030’s medical innovation investment.
Company Overview
Wandercraft was founded in 2012 by Nicolas Simon, Matthieu Masselin, and Jean-Louis Constanza — a team combining robotics engineering (Simon has a background in aerospace control systems from ISAE-Supaero and Airbus), biomechanics research, and business development. The founders’ insight was that existing lower-limb exoskeletons required too much involvement from therapists (holding handrails, providing balance assistance, manually initiating each step) to be useful for the high-repetition, high-intensity gait retraining that neurological rehabilitation research shows is necessary for functional improvement.
The Atalante’s core technical innovation is dynamic stability: unlike conventional exoskeletons that rely on patients gripping forearm crutches for balance (shifting the stability requirement to the upper body), Atalante maintains balance autonomously using a control system inspired by the balancing dynamics of bipedal walking robots. A patient using Atalante walks with hands completely free — enabling arm-swing gait training, simultaneous upper and lower limb rehabilitation, and natural gait patterns that crutch-dependent exoskeletons cannot replicate.
This hands-free operation is clinically significant. Stroke rehabilitation requires practicing normal gait patterns as frequently as possible to promote neuroplasticity — the brain’s rewiring of movement control pathways around damaged areas. Crutch-dependent exoskeletons produce abnormal gait patterns (excessive upper body compensation) that may reinforce maladaptive movement strategies rather than teaching normal walking. Atalante’s natural gait pattern addresses this clinical concern.
Headquartered in Paris, Wandercraft employs approximately 150 people with expertise across robotics, mechanical engineering, embedded software, clinical research, and medical device regulatory affairs. The Paris location provides access to France’s excellent robotics engineering talent pool (CentraleSupélec, École Polytechnique, ISAE, ENS Lyon graduate researchers) and proximity to major Parisian rehabilitation hospitals (Rothschild Foundation, Raymond-Poincaré Hospital) that served as early clinical partners.
France 2030 Medical Innovation Context
Wandercraft is positioned directly within France 2030’s health and biotherapy pillar — one of the plan’s ten strategic investment objectives. The plan’s health innovation agenda encompasses not just biopharmaceuticals and bioproduction but medical devices and digital health technologies that address major disease burdens with global commercial potential.
Bpifrance has been a consistent investor in Wandercraft, recognizing the company’s combination of deep technical excellence (robotics control systems that are genuinely world-class), clear clinical need (millions of stroke survivors globally have limited rehabilitation options), and commercial viability (medical device business models with established hospital procurement pathways). Wandercraft’s France 2030 funding has supported clinical trials that generated the evidence base for CE marking and regulatory submissions in additional markets.
France’s rehabilitation medicine infrastructure — public and private rehabilitation hospitals (SSR, Soins de Suite et de Réadaptation) managing approximately 500,000 patients per year — provides a domestic deployment market of meaningful size. Wandercraft’s Atalante is reimbursed under French hospital equipment budgets, providing commercial traction that de-risks international expansion.
The broader medical robotics context within France 2030 includes surgical robotics (where France lags significantly behind US leader Intuitive Surgical), rehabilitation robotics (where Wandercraft is leading), and rehabilitation AI (algorithmic gait analysis and treatment optimization). France 2030’s objective of building French medical technology champions that compete globally is well-served by Wandercraft’s trajectory.
Technology: The Atalante Exoskeleton
Atalante is a lower-limb powered exoskeleton — a robotic structure worn over the legs and hip that provides motorized assistance for walking while the patient’s upper body and arms remain unconstrained.
Dynamic Balancing Control: The central technical achievement is Atalante’s autonomous balance maintenance. The exoskeleton uses inertial measurement units (IMUs), joint position sensors, and a real-time model of the combined patient-robot system to continuously compute motor commands that maintain dynamic stability. This control system — based on model-predictive control techniques developed from research in bipedal robotics — computes and executes balance corrections at 1,000 Hz, responding faster than human neurological control systems could manage.
Biomechanical Adaptation: The exoskeleton’s joint ranges of motion, torque limits, and gait trajectory templates are parameterized to accommodate patient size, spasticity, and neurological condition. Clinical physiotherapists configure the system for each patient session through a tablet interface, adjusting support level, step height, stride length, and walking speed within clinically validated bounds.
Actuator Design: Atalante uses custom-designed electric actuators in the hip, knee, and ankle joints — providing sufficient torque to support the weight of a patient (up to 100 kg) while maintaining the backdrivability (the ability to move freely when external forces are applied) that allows patients to contribute their residual muscle activity to walking rather than simply being carried by the machine.
Safety Architecture: Medical robot safety requirements (IEC 60601, ISO 10218) mandate multiple redundant safety systems, emergency stop mechanisms, and fail-safe behaviors. Wandercraft’s safety architecture includes hardware e-stops, software safety monitors, physical range-of-motion limits, and therapist override capabilities that allow immediate intervention.
Clinical Data Collection: Atalante records detailed biomechanical data during each session — gait parameters, joint angles, force profiles, session duration, step counts. This data enables objective tracking of patient rehabilitation progress, which traditional physiotherapy assessment methods (observation, manual tests) cannot provide quantitatively. The anonymized population dataset from Atalante’s clinical deployments is a research asset with value for clinical research and algorithm improvement.
Clinical Evidence and Deployment
Wandercraft has published clinical research demonstrating Atalante’s safety and effectiveness in stroke rehabilitation and spinal cord injury (incomplete paraplegia). Key clinical findings include: patients walked significantly more steps per session with Atalante than with conventional physiotherapy; therapist burden was reduced, enabling longer and more intensive sessions; and patients showed improvements in walking ability at discharge that correlated with Atalante session intensity.
More than 30 rehabilitation hospitals in France, Germany, Switzerland, and Spain have deployed Atalante. The concentration in major European rehabilitation centers — rather than smaller physiotherapy practices — reflects both the device’s price point (€150,000-200,000 per unit) and the clinical context: Atalante is most appropriate for intensive inpatient rehabilitation programs that treat patients with severe neurological deficits in the days and weeks following stroke or spinal injury.
Competitive Landscape
Wandercraft competes globally with Ekso Bionics (US, EksoGT, EksoBionics), ReWalk Robotics (Israeli/US, ReWalk Personal), and Hocoma (Swiss, Lokomat — a body-weight-supported treadmill exoskeleton). Ekso and ReWalk are both publicly listed US companies with established clinical install bases and Medicare reimbursement in the US market. Hocoma’s Lokomat is the most widely deployed rehabilitation robot globally but uses a different approach (body-weight support treadmill rather than autonomous walking).
Atalante’s competitive differentiation is the hands-free walking — the autonomous balance capability that enables natural gait training without crutches or support assistance. No competitor has achieved CE marking for an autonomous-balance full lower-limb exoskeleton at Wandercraft’s commercial scale.
Investor Perspective
Wandercraft has demonstrated the commercial viability milestone that most medical robotics companies struggle to reach: a CE-marked, reimbursed device deployed in 30+ clinical centers. The investment thesis centers on expanding European hospital deployment, achieving FDA clearance for the US market, and developing next-generation capabilities (outdoor walking, stair climbing, home use) that expand the addressable market.
The US market represents the most significant commercial opportunity: the US has more stroke survivors than all of Europe, Medicare reimbursement pathways for rehabilitation robotics are established, and US rehabilitation hospitals have demonstrated willingness to pay for productivity-enhancing robotics. FDA 510(k) clearance is the key near-term commercial catalyst.
Related Companies
- Sanofi — France’s largest pharma, health innovation context
- Carmat — French artificial heart, medical device peer
- DNA Script — French biotech, health innovation peer
- Bioserenity — French connected medical devices, health tech peer
- Doctolib — French digital health platform, health innovation ecosystem